Jia Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jia Wei has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jian Xu
Department of Laboratory Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China
5 shared publications Mengxiao Xie
Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, People’s Republic of China
2 shared publicationsYi-Ning Wu
Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2 shared publications- Bartomeu Massuti
Alicante University Hospital ISABIAL, Alicante, Spain
1 shared publication - Carlos Camps
Hospital General Universitario de Valencia, Valencia, Spain
1 shared publication - Cheng Wang
Department of Pediatric Cardiovasology, The Second Xiangya Hospital, Children’s Medical Center, Central South University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 18 March 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (11)
Age-specific reference values for the 5th generation cardiac troponin T assay in Chinese children
The clinical use of the cardiac troponin T (cTnT) assay was limited to the adult population in the diagnosis and prognosis of myocardial injury. However, emerging studies indicated its significant value in the assessment of pediatric cardiology, and it has been routinely measured in most hospitals. Our study investigated the normative values of cTnT in Chinese children and reported the age-specific 99th percentile cut-off for them. A total of 1280 apparently healthy Chinese children were enrolled in our study. Serum levels of cTnT were analyzed on the Roche Elecsys Troponin T Gen 5 STAT assay. According to the Clinical and Laboratory Standards Institute C28-A3 guideline, the 99th percentile upper reference limits (URLs) with 90% confidence intervals (CIs) were calculated in different age subgroups. The 99th percentile URL was 38 (90%CI: 37.0-51.0) ng/L for 1 to P = .003), while our assay could not measure low cTnT concentrations (≥the limit of detection) in 50% girls. Our study provided age-specific URLs of cTnT for Chinese children, with the 5th generation cTnT assay from Roche Diagnostics. It had significant clinical implications in the interpretation and use of test results for pediatric cardiology.
- 18 March 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (11)
Open AccessAge-specific reference values for the 5th generation cardiac troponin T assay in Chinese children
The clinical use of the cardiac troponin T (cTnT) assay was limited to the adult population in the diagnosis and prognosis of myocardial injury. However, emerging studies indicated its significant value in the assessment of pediatric cardiology, and it has been routinely measured in most hospitals. Our study investigated the normative values of cTnT in Chinese children and reported the age-specific 99th percentile cut-off for them. A total of 1280 apparently healthy Chinese children were enrolled in our study. Serum levels of cTnT were analyzed on the Roche Elecsys Troponin T Gen 5 STAT assay. According to the Clinical and Laboratory Standards Institute C28-A3 guideline, the 99th percentile upper reference limits (URLs) with 90% confidence intervals (CIs) were calculated in different age subgroups. The 99th percentile URL was 38 (90%CI: 37.0-51.0) ng/L for 1 to P = .003), while our assay could not measure low cTnT concentrations (≥the limit of detection) in 50% girls. Our study provided age-specific URLs of cTnT for Chinese children, with the 5th generation cTnT assay from Roche Diagnostics. It had significant clinical implications in the interpretation and use of test results for pediatric cardiology.
- Open Access
- 1 August 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 7809-7818
Serum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma
Purpose: Lung cancer is a leading cause of cancer-related death, with lung adenocarcinoma (LUAD) representing the most common subtype. Recently, exosome-based biomarkers have provided new diagnostic approaches for malignancies. We aimed to identify specific exosomal microRNAs (miRNAs) as noninvasive biomarkers for LUAD. Patients and Methods: A total of 110 participants were enrolled and randomly divided into two sets: the discovery set (n=20) and the validation set (n=90). Exosomes were isolated from serum, and miRNAs were subsequently extracted. Candidate miRNAs (miR-21, miR-221-3p, miR-222-3p, miR-223, miR-638 and miR-1290) were detected by quantitative real-time PCR (qRT-PCR) in the discovery set. The upregulated miR-1290 was then selected for further analysis in the validation set along with three tumor markers (CEA, CYFRA21-1 and NSE). The diagnostic and prognostic value of exosomal miR-1290 were estimated through receiver-operating characteristic (ROC) and survival analysis. Results: Serum exosomal miR-1290 was significantly upregulated in LUAD patients compared to healthy controls (P< 0.001) and decreased after resection (P=0.0029). Its expression level was associated with tumor stage, tumor size, lymph node and distant metastasis (all P < 0.05). Exosomal miR-1290 had a higher diagnostic efficacy than CEA, CYFRA21-1 and NSE, with a sensitivity of 80.0% and specificity of 96.7% (AUC: 0.937, 95% CI: 0.890– 0.985; P< 0.001). Moreover, LUAD patients with a high level of exosomal miR-1290 had significantly poorer progression-free survival (PFS) than those with a low level of exosomal miR-1290 (mean PFS: 14 months vs 37 months, P< 0.001). Cox proportional hazards model analysis demonstrated that exosomal miR-1290 could be an independent risk factor for the prognosis of LUAD (HR=7.80, P=0.017). Conclusion: Serum exosomal miR-1290 could be a potential diagnostic and prognostic biomarker for LUAD.
- 1 August 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 7809-7818
Open AccessSerum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma
Purpose: Lung cancer is a leading cause of cancer-related death, with lung adenocarcinoma (LUAD) representing the most common subtype. Recently, exosome-based biomarkers have provided new diagnostic approaches for malignancies. We aimed to identify specific exosomal microRNAs (miRNAs) as noninvasive biomarkers for LUAD. Patients and Methods: A total of 110 participants were enrolled and randomly divided into two sets: the discovery set (n=20) and the validation set (n=90). Exosomes were isolated from serum, and miRNAs were subsequently extracted. Candidate miRNAs (miR-21, miR-221-3p, miR-222-3p, miR-223, miR-638 and miR-1290) were detected by quantitative real-time PCR (qRT-PCR) in the discovery set. The upregulated miR-1290 was then selected for further analysis in the validation set along with three tumor markers (CEA, CYFRA21-1 and NSE). The diagnostic and prognostic value of exosomal miR-1290 were estimated through receiver-operating characteristic (ROC) and survival analysis. Results: Serum exosomal miR-1290 was significantly upregulated in LUAD patients compared to healthy controls (P< 0.001) and decreased after resection (P=0.0029). Its expression level was associated with tumor stage, tumor size, lymph node and distant metastasis (all P < 0.05). Exosomal miR-1290 had a higher diagnostic efficacy than CEA, CYFRA21-1 and NSE, with a sensitivity of 80.0% and specificity of 96.7% (AUC: 0.937, 95% CI: 0.890– 0.985; P< 0.001). Moreover, LUAD patients with a high level of exosomal miR-1290 had significantly poorer progression-free survival (PFS) than those with a low level of exosomal miR-1290 (mean PFS: 14 months vs 37 months, P< 0.001). Cox proportional hazards model analysis demonstrated that exosomal miR-1290 could be an independent risk factor for the prognosis of LUAD (HR=7.80, P=0.017). Conclusion: Serum exosomal miR-1290 could be a potential diagnostic and prognostic biomarker for LUAD.
- Open Access
- 28 April 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 676
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Lung cancer is the leading cause of cancer-associated deaths worldwide, with non-small cell-lung cancer (NSCLC) accounting for approximately 80% of cases. Immune escape has been demonstrated to play a key role in the initiation and progression of NSCLC, although the underlying mechanisms are diverse and their puzzling nature is far from being understood. As a critical participant in immune escape, the CD4+ T cell subset of regulatory T (Treg) cells, with their immunosuppressive functions, has been implicated in the occurrence of many types of cancers. Additionally, therapies based on Treg blockade have benefited a portion of cancer patients, including those with NSCLC. Accumulating literature has noted high Treg infiltration in NSCLC tumor tissues, bone marrow, lymph nodes and/or blood; moreover, the tumor milieu is involved in regulating the proliferation, differentiation, recruitment and suppressive functions of Treg cells. Multifarious mechanisms by which CD4+ Treg cells are generated, attracted and modulated in the NSCLC milieu will be discussed in this review.
- 28 April 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 676
Open AccessInducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Lung cancer is the leading cause of cancer-associated deaths worldwide, with non-small cell-lung cancer (NSCLC) accounting for approximately 80% of cases. Immune escape has been demonstrated to play a key role in the initiation and progression of NSCLC, although the underlying mechanisms are diverse and their puzzling nature is far from being understood. As a critical participant in immune escape, the CD4+ T cell subset of regulatory T (Treg) cells, with their immunosuppressive functions, has been implicated in the occurrence of many types of cancers. Additionally, therapies based on Treg blockade have benefited a portion of cancer patients, including those with NSCLC. Accumulating literature has noted high Treg infiltration in NSCLC tumor tissues, bone marrow, lymph nodes and/or blood; moreover, the tumor milieu is involved in regulating the proliferation, differentiation, recruitment and suppressive functions of Treg cells. Multifarious mechanisms by which CD4+ Treg cells are generated, attracted and modulated in the NSCLC milieu will be discussed in this review.
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (6) , 1325-1333
Serum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer
Background: Pancreatic cancer (PC) is a highly malignant tumor with no effective early diagnostic biomarkers. This study was performed to screen and identify serum microRNAs (miRNAs) as noninvasive biomarkers for PC diagnosis.
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (6) , 1325-1333
Open AccessSerum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer
Background: Pancreatic cancer (PC) is a highly malignant tumor with no effective early diagnostic biomarkers. This study was performed to screen and identify serum microRNAs (miRNAs) as noninvasive biomarkers for PC diagnosis.
- 1 August 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 495, 507-511
False decrease of high-sensitivity cardiac troponin T assay in pneumatic tube system samples
- 1 August 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 495, 507-511
False decrease of high-sensitivity cardiac troponin T assay in pneumatic tube system samples
- 1 June 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 481, 121-125
Higher risk of myocardial injury in chest pain patients with elevated red blood cell distribution width
- 1 June 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 481, 121-125
Higher risk of myocardial injury in chest pain patients with elevated red blood cell distribution width
- 1 June 2010
- Published by Elsevier in Lung Cancer
- Vol. 68 (3) , 491-497
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
- 1 June 2010
- Published by Elsevier in Lung Cancer
- Vol. 68 (3) , 491-497
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients